Effect of the Interferon Alpha Citizen by Sub-Lingual Way on the Humoral Immunizing Answer

Influenza Infection Clinical Trial

— GP-INFA  

Official title:

Randomized Double-Blind Placebo Controlled Study Evaluating the Effect of Sublingual Administration of IFNa on the Immune Response to Influenza Vaccination in Subjects Aged 75 or More.

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT00647465
• Other study ID #: P050601
• Status: Terminated
• Phase: Phase 3
• First received: March 26, 2008
• Last updated: March 28, 2008
• Start date: October 2005
• Est. completion date: March 2008

Study information

• Verified date: November 2005
• Source: Assistance Publique - Hôpitaux de Paris
• Contact: n/a
• Is FDA regulated: No
• Health authority: France: Ministry of Health
• Study type: Interventional

Clinical Trial Summary

Influenza vaccination reduces the morbidity and mortality associated with influenza infection in at risk groups including the elderly and individuals with an impaired immune response, but is not totally protective in all recipient. Cytokines including type I interferons are known to play a key role in the innate immune response to virus infection and in the induction of the primary adaptive-immune response. Thus, we evaluated the safety of sublingual administration of IFNa and its effect on immune response to influenza vaccination in a randomized double-blind placebo controlled study in elderly institutionalized individuals.

Description:

The protection afforded by the commonly used influenza sub-unit vaccines is thought to be due principally to the production of antibodies to viral haemagglutinin. The haemagglutination inhibitory (HAI) antibody titer is generally used as a surrogate marker of protection and a HAI antibody titer of 1:40 or greater is considered to confer protection. This is attained, however, in only 50% of elderly subject. Thus, there is an unmet need for an effective non-toxic adjuvant capable of enhancing the antibody response to influenza and other vaccines. Type I IFNs have been shown to induce B-lymphocytes to differentiate into antibody producing plasma cells and to be necessary for the production of both specific and polyclonal IgGs in response to influenza infection. Furthermore, type I IFNs increase the primary antibody response to a soluble antigen in vivo, and increase the production of all IgG sub-classes. Type I IFNs play a key role in adjuvant-induced Th1 responses. Thus, we evaluated the safety of sublingual administration of IFNa and its effect on immune response to influenza vaccination.Institutionalized subjects, aged 75 or more, were randomly assigned to two groups to receive in a double-blind fashion either 107 IU of Intron ATM in 1 ml of isotonic saline or 1 ml of saline alone (placebo) administered sublingually. Interferon or placebo were retained in the mouth for at least 30 seconds prior to ejection. All subjects were then vaccinated, within 30 minutes, with a single intramuscular injection (im) of influenza vaccine (InfluvacTM, Solvay Pharma, France).

The primary objective of this study is to compare the immunogenicity percentage of subjects who increased up to 4 fold their HAI antibody titer at day 21) obtained in the IFN treated group relative to the placebo treated group.

The secondary objectives are to compare mean HAI antibodies titers obtained in the two groups at day 21 ; specific IgG, IgG2a, IgG2a/IgG1 ratio and secretory IgA titers in the 2 groups; specific secretory IgA titers in saliva; durability of protective HAI antibodies titers 3 and 6 months after the vaccination and the safety of sublingual administration of IFNa.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 140
• Est. completion date: March 2008
• Est. primary completion date: May 2006
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 75 Years and older

Eligibility

Inclusion Criteria:

• Subjects aged 75 or more, -institutionalized-

• Subjects who were informed of the objectives of the study and who have given their written consent.

• Subjects who have received at least one prior influenza vaccination in the previous 5 years.

• Subjects who should be vaccinated against influenza during the 2005 vaccination campaign.

Exclusion Criteria:

• Individuals with severe disease, including neoplasia, autoimmune disease, or type I diabetes

• concomitant treatment with glucocorticoid or immunosuppressive drugs splenectomy or tonsillectomy

• or incapacity to open the mouth

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Prevention

Related Conditions & MeSH terms

• Influenza Infection
• Influenza, Human

Intervention

Drug:
• vaccine
IFNalpha 2b
• Placebo
Placebo

Locations

Country	Name	City	State
France	Assistance Publique-Hôpitaux de Paris, Groupe Hospitalier Broca-La Rochefoucauld, Service de Gérontologie 1	Paris

Sponsors (2)

Lead Sponsor	Collaborator
Assistance Publique - Hôpitaux de Paris	Orakine Ltd, Dublin, Ireland

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Percentage of subjects presenting an increase > 4 fold of antiH1N1 or antiH3N2 or anti-B haemagglutination inhibition antibody titer, 3 weeks following influenza vaccination.		21 days	No
Secondary	geometric mean of haemagglutination antibody titer obtained at day 21 with or without IFNa		21 days	No
Secondary	influenza virus strain-specific IgG total, IgG2a, IgG2a/IgG1 ratio, secretory IgA responses at day 21 in each group .		21 days	No
Secondary	influenza virus strain-specific secretory IgA anti-influenza antibody titers in saliva 14 and 21 days following vaccination.		21 days	No
Secondary	evaluation of individual response to IFNa treatment		21 days	No
Secondary	levels of serologic alpha interferon and of anti- alpha -interferon at day 21.		21 days	No
Secondary	Percentage of patients maintaining protective antibody titers 3 and 6 months following vaccination.		3 months and 6 months after	No
Secondary	Predictive factors of vaccine response (age, total lymphocyte cell count, CD4 cell count…)		21 days	No
Secondary	Evaluation of cellular vaccine response in a subgroup of subjects.		21 days	No